quemliclustat
quemliclustat: sourced relationships with 1 company · 12 clinical trials tracked.
quemliclustat evidence translation
What we can confirm
12 tracked trials
What it means
What to watch
Prepared research question
How could quemliclustat → RCUS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Arcus Biosciences, Inc. (RCUS) Oligometastatic Prostate Cancer; Healthy Participants; Metas… | Phase 3 |
Clinical Trial Registry Records (12)showing 10 most recent
A Phase Ib/II Study to Evaluate the Safety and Efficacy of Enfortumab Vedotin Plus Pembrolizumab in Combination With Quemliclustat in Unresectable Locally Advanced and Metastatic Urothelial Carcinoma
Primary endpoint: Incidence of treatment related adverse events (Phase Ib)
A Phase 1, Open-Label Study to Characterize the Metabolism, Excretion, and Mass Balance of a Single Intravenous Dose of 100 mg Containing 75 µCi of [14C]-Quemliclustat in Healthy Adult Male Participants
Primary endpoint: Percentage of total radioactivity excreted in urine and feces
A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma
Primary endpoint: Overall Survival (OS)
A Phase 2, Open-Label, Multicenter, Randomized Study Evaluating Neoadjuvant Therapy Targeting the Adenosine Immunosuppressive Pathway in Combination With Immune Checkpoint Blockade and Radiation Therapy in Patients With Advanced PANCreatic Ductal Adenocarcinoma Who Are Candidates for Surgical Resection
Primary endpoint: Change in the number of intratumoral CD8+ T-cells
Study of Gemcitabine, Cisplatin, Quemliclustat (AB680) and Zimberelimab (AB122) During First-line Treatment of Advanced Biliary Tract Cancers (QUIC)
Primary endpoint: Estimate the progression free survival (PFS) with gemcitabine, cisplatin, quemliclustat (AB680) and zimberelimab (AB122) in patients with advanced BTCs.
Phase II Single Arm Study Testing SBRT, Adenosine Signaling Modulation (AB680, AB928), and Immune Checkpoint Inhibition (AB122) for Men With Hormone Sensitive Oligometastatic Prostate Cancer
Primary endpoint: Biochemical recurrence-free survival at 12-months
A Pilot Study of Zimberelimab and Quemliclustat Combination With Chemotherapy in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
Primary endpoint: Incidence of adverse events (BPRC Cohort)
A Phase II, Open-label, Platform Study, to Evaluate Immunotherapy-based Combinations in Participants With Advanced Non-Small Cell Lung Cancer
Primary endpoint: Objective response rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
A Phase 2 Trial to Evaluate the Safety and Efficacy of Combination Therapies in Patients With Advanced Upper Gastrointestinal Tract Malignancies (EDGE-Gastric)
Primary endpoint: Number of Participants with Adverse Events (AEs)
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating The Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer
Primary endpoint: Cohort A and B - Progression-free Survival (PFS)
Frequently asked questions
Which companies have sourced relationships with quemliclustat?
quemliclustat has dated SEC/FDA relationship records for Arcus Biosciences, Inc..
How many clinical trials involve quemliclustat?
BioSniper tracks 12 clinical trials involving quemliclustat.